Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology

Maya Suzuki, Kevin J. Curran, Nai Kong V. Cheung

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging.

Original languageEnglish
Pages (from-to)1326-1336
Number of pages11
JournalPediatric Blood and Cancer
Volume62
Issue number8
DOIs
Publication statusPublished - Aug 1 2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology'. Together they form a unique fingerprint.

Cite this